Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Recruiting 134Completed 97Unknown 77Terminated 41Active not recruiting 29Not yet recruiting 25Withdrawn 5Suspended 2Enrolling by invitation 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Advanced Solid Tumor × Clear all
NCT06219499 2024-04-03

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

OncoC4, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05791474 2023-11-29

ATI-2231 in Advanced Solid Tumor Malignancies

Washington University School of Medicine

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT05381935 2023-01-31

A Study of ES014 (Anti-CD39/TGF-β Bispecific Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Elpiscience Biopharma, Ltd.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04797468 2023-01-17

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Shanghai Henlius Biotech

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

NCT04878484 2022-09-02

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Athenex, Inc.

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡